Single Dose Crossover Comparative Bioavailability and Food Effect Study of Celecoxib 10 mg/1 mL Oral Suspension versus Celebrex®️ (celecoxib) 200 mg Capsules Following the Administration of a 200 mg Dose in Healthy Adult Volunteers / Fasting and Fed State.

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504052-99-00

Acronym

915/22

Enrollment

Registered

2023-06-28

Start date

2023-07-31

Completion date

2023-09-04

Last updated

2023-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute pain, Dysmenorrhea, Musculoskeletal and connective tissue disorders

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Czechia

None listed

Source: EU CTIS · Data processed: Feb 4, 2026